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ORIGINAL RESEARCH

ADULT BRAIN

Initial Investigation into Microbleeds and White Matter Signal
Changes following Radiotherapy for Low-Grade and Benign
Brain Tumors Using Ultra-High-Field MRI Techniques
X J.-G. Belliveau, X G.S. Bauman, X K.Y. Tay, X D. Ho, and X R.S. Menon

ABSTRACT
BACKGROUND AND PURPOSE: External beam radiation therapy is a common treatment for many brain neoplasms. While external beam
radiation therapy adheres to dose limits to protect the uninvolved brain, areas of high dose to normal tissue still occur. Patients treated
with chemoradiotherapy can have adverse effects such as microbleeds and radiation necrosis, but few studies exist of patients treated
without chemotherapy.
MATERIALS AND METHODS: Ten patients were treated for low-grade or benign neoplasms with external beam radiation therapy only
and scanned within 12–36 months following treatment with a 7T MR imaging scanner. A multiecho gradient-echo sequence was acquired
and postprocessed into SWI, quantitative susceptibility mapping, and apparent transverse relaxation maps. Six patients returned for
follow-up imaging approximately 18 months following their ﬁrst research scan and were imaged with the same techniques.
RESULTS: At the ﬁrst visit, 7/10 patients had microbleeds evident on SWI, quantitative susceptibility mapping, and apparent transverse
relaxation. All microbleeds were within a dose region of ⬎45 Gy. Additionally, 4/10 patients had asymptomatic WM signal changes evident
on standard imaging. Further analysis with our technique revealed that these lesions were venocentric, suggestive of a neuroinﬂammatory
process.
CONCLUSIONS: There exists a potential for microbleeds in patients treated with external beam radiation therapy without chemotherapy. This ﬁnding is of clinical relevance because it could be a precursor of future neurovascular disease and indicates that additional care
should be taken when using therapies such as anticoagulants. Additionally, the appearance of venocentric WM lesions could be suggestive
of a neuroinﬂammatory mechanism that has been suggested in diseases such as MS. Both ﬁndings merit further investigation in a larger
population set.
ABBREVIATIONS: QSM ⫽ quantitative susceptibility mapping; R2* ⫽ apparent transverse relaxation; RN ⫽ radiation necrosis; XRT ⫽ external beam radiation
therapy

E

xternal beam radiation therapy (XRT) is commonly used in
the treatment of many brain neoplasms. In benign and lowgrade neoplasms (meningiomas, neuromas, low-grade gliomas),
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safe maximal surgical resection combined with XRT is usually the
standard of care. The prescribed dose is typically a course of
54 – 60 Gy in 30 fractions using conformal delivery with techniques such as intensity-modulated radiation therapy. These dose
plans attempt to follow specific guidelines such as Quantitative
Analysis of Normal Tissue Effects in the Clinic (http://www.aapm.
org/pubs/QUANTEC.asp) to limit the dose to radiosensitive areas, including the uninvolved brain, brain stem, optic nerve, and
optic chiasm,1 as well as the hippocampus, which is known for its
role in neurogenesis.2,3 Due to the infiltrative nature of some neoplasms such as low-grade gliomas or the proximity of tumors to
normal brain in other neoplasms, even conformal radiation techniques can result in some volume of healthy tissue receiving radiation. The dose delivered to the normal brain can potentially
cause long-term effects later in the patient’s life.
Following XRT, there are numerous reports of clinical sequelae that are classified into acute, early-delayed, or late effects.4
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Acute and early-delayed adverse effects are usually temporary and
resolve spontaneously with minimal treatment or steroids. Late
effects are typically much more severe because they cause permanent changes to the brain parenchyma, including radiation necrosis (RN), cavernous angiomas, and microbleeds,4 resulting in ongoing neurologic deficits.
RN is an adverse effect that may present a few years following
XRT; however, it can occur as early as 6 months and as late as 10
years following XRT. In some patients, regions of RN may be
small and do not produce symptoms. In others, progressive RN
can be seen with detrimental effects on the patient’s quality of
life.5 Symptoms ranging from headaches and drowsiness to memory loss, seizures, and focal deficits have been documented. Treatments of RN vary from observation to steroids or antiangiogenic
agents.6 In some patients, surgical resection is required to debulk
necrotic areas to alleviate symptoms.
The exact cause of RN is not entirely understood, but the 2
main hypotheses developed in the past 50 years are related to
vascular and glial damage.4 The vascular hypothesis suggests
that radiation necrosis is secondary to an ischemic event due to
small-vessel injury, while the glial hypothesis suggests that
damage to the white matter precursor cells occurs during
XRT. Recently, the potential role of the immune response following XRT has been documented,7,8 implicating neuroinflammation as another mechanism contributing to the development of RN.
In addition to frank RN, microbleeds detected on imaging
following XRT are a recent discovery.9,10 Generally, microbleeds
are thought to be either small deposits of hemosiderin, which can
be attributed to damage to the small vessels,11; or, following radiation, microbleeds have been shown pathologically to be areas of
telangiectasia.12 Microbleeds may be indicative of future vascular
disease such as stroke.13 Microbleeds indicate not only that more
serious disease could occur in the future but also that the patient
could be put at risk of serious intracranial bleeding if started on
anticoagulants.14
Techniques such as SWI are becoming more prominent with
higher magnetic field strengths available clinically (3T) or for research (ⱖ7T). These techniques make locating microbleeds increasingly easier due to the increased SNR, which makes increased
resolution possible at higher magnetic fields, and the linear-withfield-enhancement of the paramagnetic effect of the hemosiderin
deposits. However, the increased resolution can also lead to falsepositives in microbleed detection because small venous vasculature that runs parallel to the magnetic field can be misinterpreted
as a microbleed. SWI, quantitative susceptibility mapping (QSM),
and apparent transverse relaxation (R2*) have been previously
shown to be extremely sensitive to the vasculature and hemosiderin-rich microbleeds.15-18 These techniques are also sensitive
to white matter lesions, as shown in various multiple sclerosis
studies.19,20 Previous work from Reichenbach et al21 estimated
that these techniques are sensitive to venous vasculature of approximately 100 –200 m in diameter.
Among patients with brain tumors, most studies to date have
investigated microbleeds and radiation necrosis among patients
who have high-grade neoplasms22,23; however, long-term RN
studies in this patient population may be less feasible due to the
2252
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shortened life expectancy of most patients with malignant gliomas and the difficulty in distinguishing treatment effects and tumor progression. Additionally, these studies involve patients
treated with chemotherapy, which has been shown potentially to
influence the number of microbleeds present in the brain10,24 and
may confound the estimates of microbleeds due to radiation
alone.
This initial feasibility study presents results that focus on imaging microbleeds and white matter imaging changes using SWI,
QSM, and R2* on patients treated for benign or low-grade neoplasms with radiation alone. These patients have a longer overall
survival following successful treatment and thus are at higher risk
of eventually experiencing delayed adverse XRT effects. It was
hypothesized that SWI, QSM, and R2* may be useful imaging
techniques to detect late radiation changes among this patient
population. The ability to detect such changes would then warrant a larger scale investigation for patients who might be at risk of
longer term sequelae of their treatment (cognitive effects or focal
brain injury).

MATERIALS AND METHODS
Patient Recruitment
The study was approved by the human subjects’ research ethics
board of the University of Western Ontario. Ten patients (2
men, 8 women) were recruited from our affiliated cancer program at the London Regional Cancer Program and were
screened for eligibility by the treating radiation oncologist
(G.S.B.). Eligibility requirements included patients who were
older than 18 years of age with a Karnofsky Performance Scale
score of ⬎60 and were treated for benign or World Health
Organization grade I or II brain neoplasms within 12–36
months of their recruitment for the study. Treatments for their
neoplasms could have included surgical resection followed by
radiation therapy or primary radiation therapy alone. As per
protocol, patients underwent an initial imaging session at the
time of enrollment and a second session 12–24 months later to
detect any evolution in imaging changes.

MR Imaging
Patients were scanned on a 7T MR imaging machine. This scanner
underwent an upgrade between visits for some of the patients.
Preupgrade, an Agilent/Siemens 7T MR imaging scanner (Agilent, Santa Clara, California) with a 15-channel transmit/31-receive channel coil was used. Postupgrade, a Siemens 7T Magnetom Step 2.3 MR imaging scanner (Siemens, Erlangen, Germany)
with an 8-channel transmit/32-receive channel coil was used. All
patients had their initial scan performed on the preupgrade scanner. Three patients had their second visit on the preupgrade scanner, while 3 had their second visit on the postupgrade scanner. An
anatomic T1WI was obtained (preupgrade: MPRAGE, 1-mm isotropic voxel, scan time of 5 minutes 45 seconds; postupgrade:
MP2RAGE, 0.8-mm isotropic voxel, scan time of 8 minutes 26
seconds); and a CSF-attenuated magnetization-prepared FLAIR
sequence (preupgrade: 1-mm isotropic resolution, scan time of 12
minutes 42 seconds; postupgrade: not acquired) was acquired for
registration to clinical scans. A multiecho gradient-echo (preupgrade: multiecho gradient-echo, 1 mm in-plane resolution,

1.5-mm sections, TR ⫽ 40 ms, TE ⫽ 2.4 ms, echo spacing ⫽ 3.3
ms, echoes ⫽ 6, flip angle ⫽ 13°, generalized autocalibrating partially parallel acquisition ⫽ 2.1; postupgrade: multiecho gradientecho, 1-mm in-plane resolution, 1.5-mm sections, TR ⫽ 40 ms,
TE ⫽ 4.9 ms, echo spacing ⫽ 4.5 ms, echoes ⫽ 6, flip angle ⫽ 13°,
generalized autocalibrating partially parallel acquisition ⫽ 2) sequence was acquired. A less sensitive form of imaging had to be
used postupgrade due to vendor constraints on the number of
transmit coils.

Postprocessing
The multiecho gradient-echo data set was acquired and postprocessed into SWI, R2* and QSM maps using in-house software.

QSM
The implementation of QSM used a preconjugate gradient
method25 and was compared with QSM using the MEDI toolbox
in Matlab (MathWorks, Natick, Massachusetts)17; however, the
data from the preupgrade scanner was not optimized for MEDI
processing. The algorithm uses the phase information that is temporally unwrapped over each echo with the background field contributions being removed with a Gaussian high-pass filter of 11
mm to produce the local frequency shift. The QSM image was
calculated by performing the regularized inversion demonstrated
in Reichenbach et al.21 Postupgrade data were run through both
the preconjugate gradient and MEDI toolbox; however, only data
from the preconjugate gradient method were analyzed using the
postupgrade data.

R2*
R2* was computed with a nonlinear least-squares monoexponential fit with a voxel spread function for correction.26

SWI
An 11-mm Gaussian high-pass filter was used to filter the
phase and was fit with respect to TEs using a weighted nonlinear least-squares function to calculate the local frequency-shift
map. A frequency mask of 15 Hz was then applied to an average
magnitude image from all echoes to create an SWI using inhouse software. Finally, Matlab (MathWorks) was used to create a minimum-intensity-projection image through 7 mm (7
sections) of the SWI.

Dose Plan Overlay
Treatment dose plan and planning CT and MRIs were retrieved
and were registered to the research MR imaging with the FMRIB
Linear Image Registration Tool (FLIRT; http://www.fmrib.ox.
ac.uk).27 It was found beneficial to crop the CT simulator session
to include only the head including just a few sections below the
cerebellum from the CT and a T1WI without the use of skullstripping. The matching was determined to be within the error of
the 3-mm dose grid. CERR (http://cerr.info/about.php)28 was
used to export the dose plan.

Microbleeds at visit 1 and visit 2a
Patient
1
2
3
4
5
6
7
8
9
10

Visit 1
Microbleeds
7
5
4
0
2
2
0
0
1
5

Visit 2
Microbleeds
4
X
X
0
2
0
0
0
X
X

New
Microbleeds
2
Did not return
Did not return
0
0
0
0
0
Did not return
Did not return

Resolved
Microbleeds
5
Did not return
Did not return
0
0
2
0
0
Did not return
Did not return

Note:—X indicates patient did not return.
a
All microbleeds occurred in areas of radiation of ⬎45 Gy.

dently and in a group setting established what constituted a microbleed. The microbleeds on all images were counted, and images were further assessed for vasculature and white matter
abnormalities.
Once identified, the microbleeds were manually segmented on
the SWI with ITK-SNAP 1.6 (www.itksnap.org)29 for further
analysis with R2* and QSM.

RESULTS
Clinical Findings
Ten patients consented to imaging and were enrolled in the study.
The On-line Table provides a full description of their cases, treatment, and current clinical status. A Mini-Mental State Examination was performed at the first visit, and a mean score of 29/30 ⫾
0.9 indicated that patients were cognitively intact at assessment.
Patients were imaged at a mean of 26.7 ⫾ 7.5 months following
their treatment, and 6 of 10 patients returned for a second MR
imaging between 12 and 24 months (17.3 ⫾ 7.3 months) following their first MR imaging. Four patients did not return for this
second scan. Two patients became ill for unrelated health reasons,
1 patient opted not to return for a second research scan, and 1
patient’s low-grade glioma evolved into a malignant glioma, precluding investigational re-imaging.

Radiologic Findings
No gross abnormalities or venous vessel density discrepancies
were observed on the SWI. One patient (patient 8) had a cavernous angioma that had been previously detected on conventional
MR imaging before enrollment in this study.

Microbleeds
Six of 10 patients had microbleeds on the postradiation imaging.
In all except 1 patient (patient 6), microbleeds occurred in areas of
high dose (⬎45 Gy). Some microbleeds resolved between the initial and follow-up scans. The Table reports the full list of
microbleeds. In all patients, microbleeds had an R2* of ⬎80 seconds⫺1 and QSM values lower than ⫺0.25 ppm. Most microbleeds had halo artifacts on QSM as shown in Fig 1, which aided in
their detection.

Radiographic Assessment
Images (SWI, MPRAGE, and FLAIR) were reviewed by 2 boardcertified neuroradiologists (K.Y.T., D.H.) blinded to the history
of the patient. Both radiologists reviewing the images indepen-

White Matter Lesions
Three patients had periventricular or lobar lesions on their T1WI
and FLAIR images in the mid- (⬎30 Gy) to high-dose (⬎45 Gy)
AJNR Am J Neuroradiol 38:2251–56
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regions, consistent with white matter changes reported after radiation therapy30,31 as shown in Figs 2– 4.

DISCUSSION

Searches of prior literature led us to believe that this is the first
study that investigated vasculature and white matter changes with
7T MR imaging in patients treated for low-grade or benign neoCurrent Clinical Status
As shown in the On-line Table, most patients who enrolled in this
plasms with radiation and an operation only. The potentially long
study are clinically stable following treatment for their neoplasms.
survival of this patient population posttreatment increases the
Aside from patient 10, who developed a glioblastoma, their sympchance that they may experience late radiation adverse effects
toms are not directly related to their diagnosis or treatment.
compared with patients with higher grade lesions. Imaging biomarkers that could identify patients at risk of delayed radiation
sequelae could be useful in this patient population to refine radiation-delivery techniques and to explore mitigating strategies
such as pharmacologic interventions.32
The focus of this study was to determine the feasibility of this
technique being susceptible to late effects of XRT on the normal
parenchyma (1–5 years after therapy). Gross abnormalities were
not expected because these patients were clinically stable and
monitored by conventional imaging, but it was hypothesized that
it could be possible to detect subclinical lesions in the brain receiving high doses of radiation therapy. It is known that microbleeds have appeared in patients treated with chemotherapy or
FIG 1. Patient 1 with microbleeds illustrated by the white arrow on
radiation therapy for high-grade neoplasms.10 Additionally, Liu
SWI and QSM. Haloing artifacts can be seen on QSM. Venous vascuet al17 demonstrated the ability to distinguish microbleeds from
lature is apparent in the high-dose region on SWI.
venous vasculature using quantitative
methods. Therefore, an investigation
into the occurrence of microbleeds and
white matter signal changes as a potential imaging biomarker of late radiation
effects in patients treated for low-grade
brain neoplasms was performed. While
some of the imaging indicated potentially demyelinating lesions based on the
white matter signal changes, a clinical
diagnosis was not possible.
In this cohort, 6 of 10 patients
showed microbleeds within the highdose regions; and in 5 of 6 patients, no
microbleeds were observed outside
the high-dose region. Long-term follow-up is required to correlate with
clinical end points such as future vascular incidents or cognitive adverse effects to determine whether microbleed
monitoring could be important in
these patients.
Although these patients do not
have the frequency of microbleeds as
shown in other studies of high-grade
neoplasms, the appearance of microbleeds is indicative of endothelial damage
within the high-dose region. This suggests the importance of long-term monitoring in this low-grade cohort because
these patients could be at a higher potential for symptomatic vascular or cognitive changes later in life.33,34 The apFIG 2. Patient 2 showing white matter abnormalities within the high-dose region as evidenced on pearance of microbleeds could also
indicate that further studies are required
FLAIR, R2*, and SWI.
2254
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Additionally, the high R2* can help
distinguish microbleeds and small
venules that have much lower R2* values
(20 – 40 seconds⫺1). The halo effect and
large susceptibility value of the microbleeds on QSM as shown in Fig 1 could
lead to a reduced burden for neuroradiologists when detecting microbleeds using automated methods.
A limitation of this study is the small
number of participants and an inability
to acquire follow-up imaging for all pa*
FIG 3. Patient 3 showing microbleeds on SWI and R2 (white arrow) and the white matter lesion tients. This preliminary experience illus(red arrow). Isodose lines are same as in Fig 1.
trates the feasibility of the technique in
this population and suggests that a study
of a larger cohort of patients with this imaging technique may be
warranted.
Another limitation of SWI techniques, in general, is that titanium clips used following surgery result in blooming artifacts on
postprocessed images. The artifacts are due to the magnetic field
perturbation due to these clips causing the signal to decay at a
much higher rate, resulting in more distortions with lengthened
TEs. These artifacts may lead to being unable to identify microbleeds in tissue close to the skull. Finally, SWI is limited in its ability
to view the arterioles; however, Bian et al40 have shown that arFIG 4. Zoomed-in view of Fig 3 (within the white box in Fig 3). Venous
teries and veins can be imaged in the same acquisition. This
vasculature is seen through the suspected white matter lesion.
method could also decrease false-positives and improve microbleed detection, and it would also be beneficial in observing damto look at the effect of anticoagulants. Certain studies have already
age to the arterioles.
shown that the appearance of microbleeds in other disease states
could be a contraindication for the use of anticoagulants,35 and
CONCLUSIONS
these findings suggest strategies attempting to limit radiation injury
This work is a preliminary study examining the long-term effects
using antiplatelet agents or anticoagulants in this patient population
of radiation therapy on patients treated for benign or low-grade
should be evaluated cautiously. The disappearance of microbleeds
neoplasms using ultra-high-field MR imaging. This study prebetween visits could not be considered imaging artifacts or due to
sented the potential of microbleeds in patients treated with XRT
true resolution as discussed by Yates et al.36
alone; the increased ability to detect microbleeds with ultra-highIn addition to venous vasculature being present in high-dose
field MR imaging with the use of SWI, R2*, and QSM; and the
regions, veins within the white matter lesions with high doses can
potential for white matter lesions in the high-dose area. The rebe observed as shown in Fig 4. This is a common finding in MS
sults presented in this study warrant further investigation in a
and acute disseminated encephalomyelitis.37 The white matter
larger patient cohort because these could have wide-ranging conlesions have been reported previously,30,31,38 with reports of cogsequences in the long-term management of these patients.
nitive decline. A recent communication has shown that a 43-yearold patient developed similar MS-type lesions following XRT.39
Disclosures: Jean-Guy Belliveau—RELATED: Grant: London Regional Cancer Program
Catalyst Grant, Comments: also, Canada Research Chairs Program, Canada FoundaIn MS, these lesions have been shown to have an immune retion for Innovation. Glenn S. Bauman—UNRELATED: Grants/Grants Pending: Canasponse that could be indicative of neuroinflammation. The ability
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Regional Cancer Program Catalyst Grant, Comments: London Regional Cancer Prosuggests that further studies are warranted to test this hypothesis
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